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Endothelin-converting enzyme-1 (ECE-1) is the key enzyme of endothelin biosynthesis, catalyzing the final
step in the process. In this study, we investigated the cellular distribution of ECE-1 in 19 normal human
tissues and 16 neuroendocrine tumors using immunohistochemical staining with antigen retrieval. ECE-
1 was expressed in vessel endothelial cells as well as nearly all epithelial cells, glands and duct cells in
normal human tissues including the esophagus, stomach, small intestine, appendix, colon, liver,
gallbladder, pancreas, endometrium, cervix, breast, skin, prostate, urinary bladder, lung, kidney,
sympathetic ganglion, thyroid gland, and adrenal gland. The most interesting finding was that ECE-1 was
expressed in normal neuroendocrine cells. ECE-1 was also expressed in all 16 neuroendocrine tumors,
including three paragangliomas, five pheochromocytomas, three carcinoid tumors, four medullary
carcinomas of the thyroid, and one islet cell tumor of the pancreas. In conclusion, ECE-1 is enriched in
neuroendocrine cells and neuroendocrine tumors, suggesting an important biologic role for the enzyme
in the neuroendocrine system.
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Endothelin-1 (ET-1), a 21-amino-acid peptide and potent
vasoconstrictor identified by Yanagisawa et al, is the first
member of a family of peptides with a wide variety of
biologic activities [1]. There are three ET isopeptides, ET-1,
ET-2, and ET-3. Their participation in numerous diseases,
including arterial hypertension, coronary artery disease,
pulmonary hypertension, acute renal failure, and sub-
arachnoid hemorrhage, has been suggested [2]. Recently,
ET-1 has been shown to play a crucial role in the normal
development of tissues derived from the first branchial arch
as well as of the Auerbach and Meissner intestinal plexuses
[3,4].
In humans, ET precursors are processed by two proteases
to create the mature active forms. Preproendothelins are
cleaved at dibasic sites by an endopeptidase to form
intermediates, 37–41-amino-acid peptides, termed big
endothelins (big ETs). The conversion of the inactive big
ETs to the active 21-amino-acid peptides is brought about
by the endothelin-converting enzymes (ECEs), a family of
phosphoramidon-sensitive, membrane-bound metallo-
proteases. Big ETs are cleaved at the Trp-Val bond (big
ET-1 and big ET-2) or at the Trp-Ile bond (big ET-3) to form
the final products [5–7].
Two family members involved in big ET processing
have been identified. ECE-1 is found in a variety of cells
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including endothelial cells. It processes big ETs both
intracellularly and on the cell surface. ECE-2, thought to be
an intracellular processing enzyme, is located in diverse cell
types, including neurons [2]. Recently, ECE-1 has been
characterized biochemically from rat lung microsomes [8,
9], porcine and bovine endothelial cells and tissues [10,11],
and human umbilical vein [12]. Furthermore, ECE-1 cDNA
has been identified and cloned in rat [13], bovine [11], and
human endothelial cells [14]. There are four isoforms of
ECE-1 (ECE-1a, ECE-1b, ECE-1c, and ECE-1d) which share
a common C-terminal region [15].
Only limited data about the expression of ECE-1 protein
are available in humans as yet [14,16]. ECE-1 levels are
particularly high in human cardiovascular, reproductive,
and endocrine systems [16]. The aim of this study was to
investigate the ECE-1 distribution in human normal tissues
and neuroendocrine tumors using antigen retrieval
immunohistochemical staining in formalin-fixed, paraffin-
embedded human tissues.
MATERIALS AND METHODS
Human tissues
Nineteen normal human tissues were obtained at surgery
from tumor-free or disease-free resection margins in nine
patients undergoing resections for various reasons (e.g. tumor
resection). The ages of these patients ranged from 26 to 71
years, and there were six males and three females. Tissue from
16 neuroendocrine tumors, including three paragangliomas,
five pheochromocytomas, three carcinoid tumors (one in the
appendix and two in the rectum), four medullary carcinomas
of the thyroid, and one islet cell tumor of the pancreas, were
also obtained at surgery from 16 patients undergoing tumor
resection. The ages of these patients ranged from 46 to 68 years,
and there were 11 males and five females. All normal and
tumor tissues were stored as paraffinized tissue blocks in the
archives of Tzu-Chi General Hospital. Histologic review of
normal tissues confirmed that these were from the esophagus,
stomach, small intestine, appendix, colon, liver, gallbladder,
pancreas, skin, prostate, urinary bladder, endometrium, cervix,
breast, lung, kidney, sympathetic ganglion, thyroid gland, and
adrenal gland.
Human ECE-1 antibody
Antibody against human ECE-1 was produced by immunizing
rabbits with a synthetic peptide, CPPGSPMNPPHKCEVW,
that corresponded to the C-terminal of 16 amino acids of
human ECE-1 [14,17]. This sequence is common to ECE-1a,
-1b, -1c, and -1d [15], meaning that our antibody was
directed against all four isoforms of ECE-1. The synthetic
C-terminal 16-amino-acid peptide was custom made by
Genesis/Sigma (St Louis, MO, USA). Rabbit anti-ECE-1
antiserum was made by Cashmere Biotech (Taipei, Taiwan)
using the synthetic ECE-1 peptide conjugated to keyhole
limpet hemocyanin. A 2-week immunization protocol was
followed. Antibody titers were examined using an enzyme-
linked immunosorbent assay. Antibody was further purified
from the antiserum in our laboratory using affinity columns
(AminoLink column, Pierce Biotechnology Inc, Rockford,
IL, USA) prepared from agarose gel coupled with the
synthetic ECE-1 C-terminal peptide.
Western blotting
The specificity of the antibody was assessed using Western
blotting. Frozen human liver and esophagus tissues were
homogenized. The homogenate was centrifuged at 200g for
10 minutes and the resulting supernatant was further
centrifuged at 48,000g for 20 minutes. The crude membrane
pellet obtained was solubilized in Laemmli sample buffer
(Bio-Rad Laboratories Inc, Hercules, CA, USA) containing
50 mM dithiothreitol. Total proteins were subjected to 10%
SDS-polyacrylamide gel electrophoresis and blotted to
polyvinylidene fluoride transfer membranes (Immobilon-
P, Millipore, Bedford, MA, USA). These membranes were
incubated with the affinity-purified human ECE-1 antibody,
horseradish peroxidase-conjugated anti-rabbit IgG (Pierce
Biotechnology Inc) and then subjected to enhanced chemi-
luminescence using the ECL detection kit (Amersham
Biosciences UK Ltd, Little Chalfont, Buckinghamshire, UK)
as recommended by the manufacturer.
Immunohistochemistry
Individual tissue sections of 4 µm to 5 µm were
deparaffinized and heated in 10 mM citric acid mono-
phosphate buffer (pH 6.0) for 30 minutes in a 1.35 kW
microwave oven at high power [18]. In preliminary
experiments, this method of antigen retrieval enhanced the
recognition of antigen in archival tissues. If the antigen-
retrieval technique was not used, only faint, patchy staining
was observed with anti-ECE-1 antibody. In contrast, after
microwave treatment of the sections, the antibody produced
distinct granular cytoplasmic staining in identical patterns.
To minimize the evaporation of buffer during heating, the
tissue slides were microwaved in a non-metallic kitchen
pressure cooker.
Immunohistochemical staining was performed using
labeled streptavidin from a complex kit (LSAB kit, Dako,
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Copenhagen, Denmark). The staining procedure involved
sequential application of the following antibodies: primary
rabbit anti-ECE-1 antibody (1:200), a biotinylated anti-rabbit
and anti-mouse secondary antibody (Dako) for 30 minutes,
and a streptavidin peroxidase conjugate (Dako) for a further
30 minutes. After each incubation, the tissue sections were
rinsed three times with cold phosphate-buffered saline
(5 minutes each).
Following treatment with a Chromogen-AEC kit (Dako),
immunoprecipitate formation sites were identified using light
microscopy. Positive and negative control sections were
incubated with each assay. The negative control slides were
processed identically except that the primary antibody was
omitted. Samples were regarded as positive for ECE-1 when
distinctive cells revealed granular cytoplasmic deposits [16].
RESULTS
Western blotting
The transferred membrane proteins from human liver and
esophagus contained one single band, about 120 kd in
molecular weight, which reacted with the affinity-purified
anti-human ECE-1 antibody (Figure 1).
Figure 2. Human ECE-1 protein is expressed in the ductal epithelium of
the breast. (3-amino-9-ethylcarbazole, AEC, × 200.)
Figure 1. Detection of endothelin-converting-enzyme-1 (ECE-1) in cell
membranes by Western blotting. Membrane proteins from human liver (A)
and esophagus (B) were resolved on a 10% SDS-polyacrylamide gel under
reduced conditions, transferred to PVDF (polyvinylidene difluoride)
membranes and immunoblotted with a rabbit polyclonal antibody directed
against the C-terminal peptide of the human ECE-1. Western blotting
showed a single band, detected by the ECE-1 antibody, of about 120 kd.
Numbers on the left show the position of molecular weight markers.
Figure 3. Human ECE-1 protein expressed in follicle cells and C cells
(arrow) of the thyroid. (AEC, × 200.)
Immunohistochemistry
ECE-1 rabbit polyclonal antibody was highly reliable and
specific, providing reproducible, clear staining with no
nonspecific background staining (Figures 2–11). Negative
controls showed no nonspecific immunostaining (not
shown).
Normal tissues
ECE-1 immunoreactivity was detected in all endothelial
cells of vessels, nearly all epithelial cells, and gland or duct
tissues in the 19 normal human tissues. In the breast, ECE-
1 was expressed in the ductal epithelium (Figure 2). The
thyroid gland showed ECE-1 protein expression in follicle
cells (Figure 3) while the adrenal gland showed ECE-1
 A B
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protein expression in adrenal cortical cells as well as
chromaffin cells of the adrenal medulla (data not shown). In
the kidney, ECE-1 immunoreactivity was detected in renal
tubules and mesangial cells of the glomerulus (Figure 4). In
the gastrointestinal tract, ECE-1 was expressed in smooth
muscle and mucous glands (Figure 5). In addition, ECE-1
protein localized in all neuroendocrine cells, including
argentaffin cells of the gastrointestinal tract (Figure 5), C
cells of the thyroid (Figure 3), ganglion cells of the
sympathetic ganglion (Figure 6), islets of Langerhans (Figure
7), and chromaffin cells of the adrenal medulla. However,
there was no ECE-1 immunostaining in the acinar cells or
duct epithelium of the pancreas (Figure 7).
Neuroendocrine tumors
All 16 neuroendocrine tumors showed strong ECE-1
immunostaining in the cytoplasm. In carcinoid tumors of
the appendix, ECE-1 was expressed in the cytoplasm of
island-like lobular masses of cells (Figure 8). In paragan-
gliomas and pheochromocytomas, ECE-1 was expressed in
Figure 4. Human ECE-1 protein is expressed in the cytoplasm of tubular
epithelium (large arrows) and mesangial cells of the glomerulus of the
kidney (small arrows). (AEC, × 200.)
Figure 5. Human ECE-1 protein expressed in the mucous glands (1),
argentaffin cells (2), and smooth muscle (3) of the colon. (AEC, × 200.)
Figure 6. Human ECE-1 protein is expressed in the cytoplasm of the
sympathetic ganglion. (AEC, × 200.)
Figure 7. Human ECE-1 protein is expressed in the islet cells of the islets
of Langerhans in the pancreas. There was no ECE-1 immunostaining in
the acinar cells (1), or ductal cells (2). (AEC, × 100.)
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the cytoplasm of chromaffin cells in a trabecular pattern
(Figure 9). In medullary carcinomas of the thyroid, ECE-1
protein was localized in neoplastic C cells embedded in the
amyloid stroma (Figure 10). In addition, in the islet cell
tumor, ECE-1 protein was localized in the cytoplasm of islet
cells in an insular pattern (Figure 11).
DISCUSSION
On Western blots, a single band, about 120 kd, reacted with
the affinity-purified, anti-human ECE-1 C-terminal peptide
antibody (Figure 1). Similar results were described in a
study that used an antiserum directed against human
ECE-1a (residues 473–489), which detected a band at about
120 kd in membrane proteins obtained from Chinese hamster
ovary cells transfected with human ECE-1 cDNA [19].
In normal human tissues, ECE-1 expression was not
limited to endothelial cells in the organs examined but was
also detected in mesenchymal and epithelial cells. The
strongest staining was associated with vascular endothelial
cells in most organs. This is consistent with the work of
Korth et al [16], who studied human ECE-1 mRNA and
protein in various human tissues, and Xu et al [11], who
Figure 8. Human ECE-1 expressed in the cytoplasm of carcinoid tumor
of the appendix. (AEC, × 100.)
Figure 9. Human ECE-1 expressed in the cytoplasm of a pheo-
chromocytoma of the adrenal gland. (AEC, × 100.)
Figure 11. Human ECE-1 expressed in the cytoplasm of islet cell tumor
of the pancreas. (AEC, × 200.)
Figure 10. Human ECE-1 expressed in the cytoplasm of medullary
carcinoma of the thyroid. (AEC, × 200.)
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studied bovine ECE-1 mRNA levels in endothelial cells
from various tissues. We found ECE-1 immunoreactivity in
nearly all epithelial cells and glands as well as duct tissues
in normal human tissues, including the esophagus, stomach,
small intestine, appendix, colon, liver, skin, prostate, urinary
bladder, breast, lung, kidney, and thyroid gland, which
agrees with the findings of a previous report showing
expression of the ECE-1 protein in the same normal human
tissues [16]. In addition, we demonstrated that ECE-1 protein
was expressed in the gallbladder, endometrium, and cervix.
Korth et al reported moderate ECE-1 immunoreactivity in
the acinar cells and ducts of the pancreas [16], but we found
no such immunoreactivity (Figure 2). It is not clear whether
the difference in immunoreactivity in the acinar cells and
pancreatic ducts was due to differences in experimental
conditions, including using different antibodies. Korth et al
used an antiserum against a synthetic peptide corresponding
to the amino acids 473–489 of human ECE-1a [16,19], while
we used an antibody against the C-terminal 16-amino-acid
peptide of human ECE-1.
The strongest staining was found in neuroendocrine
cells such as islet cells, C cells in the thyroid, argentaffin
cells in the gastrointestinal tract, ganglion cells in the
sympathetic ganglion, and chromaffin cells in the adrenal
medulla. These results agree with a previous study, which
showed moderate ECE-1 immunoreactivity in islet cells,
the enteric ganglion, and the adrenal medulla [16]. Therefore,
ECE-1 is expressed in diverse neuroendocrine tissues,
suggesting an important biologic role for the enzyme in the
neuroendocrine system.
We also investigated ECE-1 protein expression
in neuroendocrine tumors. ECE-1 protein has been detected
in many types of tumors, including lung [20], colon [21],
and endometrial cancers [22]. ECE-1 gene expression has
been described in pheochromocytoma [23].  We
demonstrated, for the first time, the expression of ECE-1
protein in various human neuroendocrine tumors, including
carcinoid tumor, paraganglioma, pheochromocytoma,
medullary carcinoma of the thyroid, and islet cell tumor
of the pancreas. Our results were in good agreement with
a previous report showing expression of the ECE-1 gene
in pheochromocytoma [23]. We found that all the
neuroendocrine tumors examined expressed ECE-1 protein
strongly in the cytoplasm. The expression of ET-1,
the product of the enzyme ECE-1, has been identified in
many human cancer cell lines and tumors, including
prostate, ovarian, lung, colon, renal, cervical, and glioma
tumors [24]. Further studies with more tumor specimens
are required to investigate details of ECE-1 expression in
neuroendocrine tumors, such as the percentage of tumors
expressing ECE-1 and the correlation of ECE-1 expression
with tumor progression.
In conclusion, we found that ECE-1 protein is strongly
expressed in vascular endothelial cells and moderately
expressed in nearly all epithelial cells as well as the glands
or ducts in normal human tissues. In addition, ECE-1 is
highly enriched in both normal neuroendocrine cells and in
related tumors, including paraganglioma, pheochromo-
cytoma, carcinoid tumor, medullary carcinoma of the
thyroid, and islet cell tumor of the pancreas, suggesting an
important biologic role for the enzyme in the neuroendocrine
system.
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